Core Viewpoint - Jiangsu Huiju Pharmaceutical Co., Ltd. has successfully transitioned from raw materials to high-end formulations, with its first oral sustained-release formulation, Fenobert Choline, recently approved by the National Medical Products Administration, marking a significant milestone for the company [1][2]. Group 1: Company Development - The company was founded in 2000 and has over 160 raw materials in production, serving more than 300 global clients [2]. - The company has invested over 1 billion yuan in a high-end formulation R&D, transformation, and manufacturing integrated platform project, which is currently under construction [2][3]. - The first formulation product, Acetylcysteine Injection, was approved for market entry in December 2024, and it won supply rights in six provinces in China [3][4]. Group 2: Strategic Focus - The company aims to build a complete industrial chain by integrating R&D, transformation, production, and sales, aligning with modern pharmaceutical industry trends towards automation and efficiency [3][4]. - The company is focusing on high-tech areas with significant potential, such as oral dissolving films, fully isolated anti-cancer drug formulations, freeze-dried tablets, and capsules [4]. Group 3: Talent and Innovation - The company faces challenges in transitioning from raw materials to formulations, including high technical barriers and a shortage of professional talent [5]. - The company has implemented attractive talent recruitment and incentive policies to create a conducive environment for talent retention and development [5][6]. - The company has increased its R&D efforts in innovative drugs, addressing critical issues in the domestic biopharmaceutical sector and promoting localization and cost reduction [6].

Group 1 - The biopharmaceutical industry is a rapidly growing strategic emerging industry globally, with significant government support and innovation driving its development [5][7] - The global biopharmaceutical market grew from $261.1 billion in 2018 to $363.8 billion in 2022, with a compound annual growth rate (CAGR) of 8.6%, and is expected to reach $783.2 billion by 2030, with a CAGR of approximately 10.1% from 2022 to 2030 [5] - In China, the biopharmaceutical market is projected to grow from $45.2 billion in 2019 to $66.5 billion in 2023, with a CAGR of 10.13%, and is expected to reach $162.8 billion by 2030, with a CAGR of approximately 13.64% from 2023 to 2030 [7] Group 2 - The company specializes in the production and sales of biopharmaceuticals, including the first commercialized nerve growth factor product, Jinlujie, which has been widely used in clinical applications for nerve injury repair [15][16] - The company’s subsidiary, Tianjin Hankan, is a well-known CRO-CDMO integrated service provider, offering a comprehensive range of drug development services from research to clinical trials and production [11][22] - The company has developed over 200 products for more than 600 enterprises, with significant achievements in the development of generic drugs and innovative drugs [12][11] Group 3 - The company has received various accolades, including being recognized as a "National Specialized and New 'Little Giant' Enterprise" and ranking among the top 50 innovative enterprises in the pharmaceutical industry [13] - The company’s product pipeline includes innovative drugs such as injection of Epinavamine, a targeted anti-tumor drug, and other pharmaceutical products that address various medical needs [17][18][20] - The company has made significant advancements in drug registration, with several products receiving approval from the National Medical Products Administration [37]